Actemra, Long-Term Special Drug Use Surveillance in Takayasu arteritis and Giant cell arteritis patients

Actemra, Long-Term Special Drug Use Surveillance in Takayasu arteritis and Giant cell arteritis patients - Actemra, Long-Term Special Drug Use Surveillance in TAK/GCA patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029056

Enrollment

240

Registered

2017-09-13

Start date

2017-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Takayasu arteritis, Giant cell arteritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have no medical history of Actemra SC and IV for TAK or GCA for the last 6 months.

Exclusion criteria

Exclusion criteria: No criteria

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events and adverse drug reactions Daily fluctuation of corticosteroid Changes in clinical features of TAK/GCA Rate of relapse, etc.	—

Countries

Japan

Contacts

Public ContactAyaka Shimizu

Chugai Pharmaceutical Co. Ltd. Real World Data Science Dept.

shimizuayk@chugai-pharm.co.jp03-3273-0905

Outcome results